Failure to launch: white paper explores the role of inappropriate use of IP in blocking access to generic and biosimilar medicines

White Paper: Anatomy of a failure to launch: A review of… 5 November 2020 Open
Access to medicines and security of supply should be central… 13 June 2023 Generic and biosimilar medicines significantly lower healthcare treatment costs and…
Smart reform of EU pharma and IP legislation key to boosting… 28 June 2022 Generic and biosimilar medicines lower healthcare treatment costs dramatically and…
A new medicines trade and health security agenda for the… 19 February 2021 In response to the European Commission Trade Communication published on…